Chimps share with children sense of curiosity for social interactions

Chimpanzees share a sense of curiosity with children and enjoy watching social interactions in a similar way, according to a study.
An international team of researchers found that chimpanzees and young children prefer to watch videos of social interactions compared to videos of a single individual.
They also found that young children and male chimpanzees were even willing to give up a treat to watch the videos.
The study involved three experiments carried out at the Ngamba Island Chimpanzee Sanctuary in Uganda and at Oakland Zoo and the Lawrence Hall of Science in California.
The researchers built two 'curiosity boxes' which held tablets playing different videos with one showing social interaction such as grooming, playing or arguing with the other showing just an individual acting alone.
In the first experiment involving chimpanzees and children aged between four and six, they found that both species spent more time watching the social scenes.
In the second, the participants had to choose between a reward – jackfruit seeds for chimps and marbles for children – for the chance to watch a social video.
They found that some younger children and male chimpanzees would choose the video over the treat.
For the third experiment, they tested whether the participants preferred watching positive interactions such as grooming or play or negative ones such as conflict.
They found the chimpanzees did not appear to show a strong preference, while the humans did.
The researcher said boys as they got older preferred negative scenes while the girls were more interested in positive ones.
Dr Esther Herrman, of the University of Portsmouth's Centre for Comparative and Evolutionary Psychology, who co-authored the research, said: 'This study tells us that curiosity about what others are doing – what you might call being a bit nosy – starts young and runs deep.
'It's probably something that helps not only us but also our closest living relatives to survive and thrive in complex social groups.'
She added: 'This kind of social curiosity is actually really important for learning about our environment, making decisions and building relationships.'
The researchers say the study results, published in Proceedings of the Royal Society B: Biological Sciences, indicate that human curiosity could be a trait inherited millions of years ago from a common ancestor we had with chimpanzees.
Lead author, Dr Laura Simone Lewis at the University of California in Santa Barbara, said: 'Our strong interest in the lives of others – think gossip magazines and celebrity shows – seems to have deep evolutionary roots in our great ape lineage.'

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Medical News Today

an hour ago

• Medical News Today

Rapamycin may extend lifespan as effectively as dietary restrictions

Research is ongoing about potential strategies to prolong life. A meta-analysis found that the drug rapamycin prolongs life in several vertebrate appeared to prolong life at a level similar to dietary restrictions. How to prolong life is a key area of scientific research. Experts are interested in medications that have the potential to boost longevity.A recent meta-analysis published in Aging Cell explored how rapamycin and metformin influenced longevity among several results confirmed that dietary restriction appears to prolong life and that rapamycin offers similar benefits. Researchers also found that metformin did not seem to prolong life. More research is required to see how rapamycin might help boost longevity in people. Rapamycin: Does it increase lifespan?In this paper, researchers note that decreasing food intake without malnourishment appears to prolong life but that this strategy is difficult for people to stick to. Thus, looking into possible medications that produce similar effects is an area of research. The two medications that were the focus of this analysis were rapamycin and metformin. According to the National Cancer Institute, rapamycin has a few functions, such as being an immunosuppressant and antibiotic, and it can help people who get helps with type 2 diabetes management. This analysis involved a systematic literature search to find relevant data. The final analysis included data from 167 papers looking at eight total vertebrate species, seeking to see how both medications affected longevity and how they compared to dietary extracted information on average and median lifespan from the papers. For this analysis, the two types of dietary restriction were caloric reduction and fasting, and researchers also sought to see if the results differed based on the sex of the animals involved. The data came from animals like mice, rats, turquoise killifish, and rhesus macaques. Overall, there were more males studied than females. There was also the most data on dietary restriction, and the most common type of dietary restriction was decreasing the number of calories. Regarding dietary restriction, the findings suggested great variation regarding the effects. Overall, researchers found that dietary restriction and rapamycin had a similar impact and appeared to contribute to prolonged life. Metformin appeared to only have a minimal impact on life from one metformin model, there appeared to be no consistent differences between male and female animals regarding longevity. Study author Zahida Sultanova, PhD, a Leverhulme Early Career Research Fellow with the University of East Anglia, in the United Kingdom summarized the key findings of the study to Medical News Today: 'We checked whether the two best-known 'diet-mimic' drugs increase lifespan similar to eating less in animals. By pooling data from 167 studies, we found that rapamycin is almost as reliable as eating less for increasing lifespan, whereas metformin is not. In other words, a compound that was extracted from soil bacteria 50 years ago seems able to copy many of the biological effects of a permanent diet, at least in lab animals.'Do the same benefits apply to people?This research analyzed animal data but did not include data about people. Additionally, most of these studies involved these animals in a laboratory setting and only looked at a small number of meta-analysis was also the work of only three researchers, sometimes with only one researcher doing a component of the work, which could have impacted the had the least amount of data on metformin, so more research about this medication might be helpful. They also operated under the assumption that if a paper did not specify male or female subjects, it was a mixed group, which could have been incorrect. The authors further note that the 'results were sensitive to how lifespan was reported.' Researchers also acknowledge strong publication bias and a lot of heterogeneity. Additionally, the type of measure used in study reporting affected results. In one measurement, the impact on life extension disappeared for the most part, the authors did not find a consistent difference in results based on the sex of the animals. They explain this could be because of 'differences in taxonomic groups studied […] and the calculated effect size.' Sultanova noted the following cautions regarding the findings: 'This study includes a high number of scientific studies conducted on different organisms such as mice, fish and monkeys. However, survival results in humans are not included because these drugs were not tested in humans for lifespan extension. Even if they are, the studies will take a long time considering the length of human lifespan. So, we do not recommend people to take rapamycin before the results of human trials consistently show that there are no side effects.'Why is it hard to study rapamycin in humans?Researchers suggest the need for research involving other species in natural and laboratory settings. They also note the need to understand the difference in impact for 'different strains of the same species exposed to the same treatment.'Future research can further focus on the differences between rapamycin and metformin and why they impact lifespan differently. More research into the differences in rapamycin's results in males and females could be helpful as well. More research can be done to see if rapamycin can promote prolonged life in people, but there may be some challenges in this Ali, MD, a board-certified general surgeon, bariatric surgeon, and medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in Fountain Valley, CA, who was not involved in the study, told MNT that it 'shows the contribution of the immune system to lifespan, as rapamycin is an immunosuppressive medication.'According to him: 'The most logical next step is to explore the findings in humans; however, this would be a difficult study to design as rapamycin is a medication used in specific cancers and organ transplant and has significant side effects.'Despite this, the results show a potential benefit of rapamycin that warrants more explained that: 'Clinically, that puts rapamycin (and the mTOR pathway it targets) at the front of the queue for future anti-ageing therapies in humans. The compound had already been used for organ-transplant patients, so medical professionals understand its potential side effects.''The next step is waiting for the results of ongoing human trials that test lower and intermittent doses of rapamycin and refining the compound to 'rapalog' versions that keep the benefits while omitting side-effects such as immune suppression,' she told us.'Another important next step would be developing drugs that are similar in structure and function to rapamycin but without the side-effects. Scientists have already started refining rapamycin and producing the so-called rapalogs,' Sultanova noted.

The Guardian

2 hours ago

• The Guardian

Giant asteroid could crash into moon in 2032, firing debris towards Earth

If a giant asteroid smashes into the moon in 2032 it could send lunar debris hurtling towards Earth, researchers have said, posing a risk to satellites but also creating a rare and spectacularly vivid meteor shower visible in the skies. Asteroid 2024 YR4 triggered a planetary defence response earlier this year after telescope observations revealed the 'city killer' had a 3% chance of colliding with Earth. Later observations found the likelihood of the asteroid, estimated at about 53-67 metres (174-220ft) wide, hitting the Earth was negligibly low at 0.0017% – although the moon would still be under threat. The odds of the space rock hitting Earth's nearest neighbour have since risen to 4.3%, according to data from the James Webb space telescope. A study released this month by researchers from Canadian universities, which has not been peer reviewed, has mapped out how the asteroid's impact on the moon may shear off rocks that could head for Earth. Researchers simulated how the impact could create a roughly 1km-diameter crater in the moon's surface and launch millions of kilograms of debris out of the moon's orbit and towards Earth, where it would arrive days later. 'If 2024 YR4 strikes the moon in 2032, it will (statistically speaking) be the largest impact in approximately 5,000 years,' the report said. 'The resulting meteor shower at Earth could be eye-catching.' While many of the millimetre- to centimetre-sized lunar rocks would burn up in Earth's atmosphere and present no threat to humans, some material could be captured in Earth's orbit, presenting a hazard to satellites, spacecraft and astronauts. The study's lead author, Dr Paul Wiegert of the University of Western Ontario, told Agence France-Presse that the impact on the moon's surface would be 'comparable to a large nuclear explosion in terms of the amount of energy released'. 'A centimetre-sized rock travelling at tens of thousands of metres per second is a lot like a bullet,' he added. The findings showed that 'planetary defence considerations' should be extended to cover threats to areas far away from near-Earth space, the study said. Nasa and other national space agencies have long tracked asteroids and comets that could threaten the planet – and are working on ways to deal with a possible collision – but the moon is of secondary concern. In 2022, Nasa conducted a test to divert an asteroid when it smashed its Double Asteroid Redirection Test (Dart) spacecraft into one named Dimorphos, successfully altering its orbit trajectory. The mission was seen as a test run for future celestial bodies that may be on a course for Earth. Asteroid 2024 YR4, which orbits the sun, is now too far away to be properly observed and is not expected to be visible again until 2028, when researchers can reassess its size and trajectory. Despite earlier concerns that an impact with the moon might alter its orbit around Earth, Nasa ruled out that scenario in April when it reassessed its size. Agence France-Presse contributed to this report

The Independent

3 hours ago

• The Independent

The fasting strategy that scientists suggest rivals the most effective methods

A new study indicates alternate-day fasting is more effective at boosting metabolism compared to both calorie restriction and intermittent fasting. An analysis of 99 clinical trials found alternate-day fasting was the only dietary strategy to provide a modest benefit in reducing body weight compared to continuous calorie restriction. This form of fasting was also associated with lower levels of total and LDL, or 'bad' cholesterol when compared to time-restricted eating. Researchers noted that alternate-day fasting did not meet the clinically significant threshold of at least 2kg of weight loss for individuals with obesity. The study concluded that longer-duration trials are needed to further substantiate these findings and understand the long-term effects of various dietary strategies.